Latest news from Benu BioPharma, Inc. on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/benu-bioventures-to-finance-early-biopharmaceutical-clinical-development/?sc=rsin /articles/benu-bioventures-to-finance-early-biopharmaceutical-clinical-development/?sc=rsin Mon, 16 Sep 2013 10:00:00 EST Benu BioPharma announced today the establishment of Benu BioVentures, a new biopharmaceutical investment initiative to fund and develop preclinical stage pharmaceutical investments to the human proof-of-concept stage. Leveraging Benu BioPharma's management expertise in technology commercialization and pharmaceutical development, Benu BioVentures is creating and financing virtual companies that will develop candidate drugs in a cost and time efficient manner. Funding activities will focus on product candidates with strong animal data and a clear regulatory path that address unmet medical needs. Benu BioVentures is led by Dennis Goldberg, Ph.D., FAHA and Fred Meyer, Ph.D., CFA, both recognized biopharmaceutical serial entrepreneurs. Benu BioPharma, Inc.